Clinical Trial

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

Suspended Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Participant recruitment has been stopped because the planned sample size has been reached.
Summary
This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-08; most recent amendment 2026-04-14.
Trial Details
NCT Number NCT07529535
Lead Sponsor Zhejiang Anglikang Pharmaceutical Co., Ltd.
Conditions Advance Solid Tumors
Enrollment 16 participants
Start Date 2025-06-05
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-17